← Drug-vs-drug verdicts

CagriSema vs Wegovy (2026): Phase 3 Data vs FDA-Approved Semaglutide

CagriSema (cagrilintide + semaglutide, Novo Nordisk) vs Wegovy (semaglutide, Novo Nordisk)

Last verified 2026-07-06

By Eli Marsden · Founding Editor
Editorially reviewed (not clinically reviewed) · How we verify contentLast reviewed

The verdict

CagriSema (cagrilintide + semaglutide 2.4 mg) produced ~20.4% mean body-weight loss at 68 weeks in the REDEFINE-1 phase 3 trial (PMID 40544433) and outperformed semaglutide monotherapy by ~6.5 percentage points in a direct head-to-head RCT (PMID 42009015) — the strongest available comparison between these agents. Wegovy (semaglutide 2.4 mg alone) achieved ~14.9% weight loss in STEP-1 (PMID 33567185) and, critically, reduced major adverse cardiovascular events by 20% in the SELECT trial (PMID 37952131) — the only obesity drug with a proven CV outcomes benefit as of 2026. CagriSema is investigational and not FDA-approved; it is unavailable outside clinical trials as of mid-2026, and Novo Nordisk has not confirmed a regulatory submission date. Cross-trial efficacy comparisons carry population-difference caveats, but head-to-head evidence clearly favors the dual-agent over semaglutide alone on weight loss. Patients who need treatment today should use Wegovy; CagriSema's approval may add a more potent choice if cleared by the FDA.

Side-by-side comparison

FieldCagriSemaWegovy
Peak weight loss (vs placebo)~20.4% at 68 wk — REDEFINE-1 (PMID 40544433)~14.9% at 68 wk — STEP-1 (PMID 33567185)
Head-to-head vs semaglutide-18.4% in direct phase 3a RCT vs semaglutide (PMID 42009015)-11.9% semaglutide arm in same direct RCT
Mechanism of actionDual amylin receptor + GLP-1 receptor agonist (cagrilintide + semaglutide 2.4 mg)GLP-1 receptor agonist (semaglutide 2.4 mg)
Cardiovascular outcomesNo completed CV outcomes trial; data pending20% MACE reduction in SELECT trial, 2023 (PMID 37952131)
FDA approval statusInvestigational — not FDA-approved (as of mid-2026)FDA-approved for chronic weight management since June 2021
AdministrationOnce-weekly subcutaneous injection (investigational)Once-weekly subcutaneous injection (0.25–2.4 mg, dose escalation)
Commercial availability & priceNot commercially available — clinical trials onlyAvailable by prescription; ~$499/mo with savings programs

Frequently asked questions

Is CagriSema better than Wegovy for weight loss?

Trial data strongly suggest yes — CagriSema produced ~20.4% weight loss in REDEFINE-1 versus Wegovy's ~14.9% in STEP-1, and a direct head-to-head RCT showed CagriSema beating semaglutide monotherapy by ~6.5 percentage points. However, CagriSema is investigational and not FDA-approved, so it cannot be prescribed outside clinical trials as of mid-2026.

When will CagriSema be FDA-approved?

As of mid-2026, Novo Nordisk has not announced an NDA submission date for CagriSema in obesity. Phase 3 results were published in 2025, and a regulatory filing is anticipated, but no approval timeline has been officially confirmed.

Does Wegovy have heart-benefit data that CagriSema lacks?

Yes. The SELECT cardiovascular outcomes trial (PMID 37952131) showed Wegovy reduced major adverse cardiovascular events by 20% in adults with obesity and existing heart disease — the first obesity drug with an FDA-approved cardiovascular indication. CagriSema has no completed CV outcomes trial.

Can I switch from Wegovy to CagriSema now?

No — CagriSema is investigational and not commercially available. If you are interested in access, check ClinicalTrials.gov for open REDEFINE follow-on or extension studies.

Do CagriSema and Wegovy have different side effects?

Both share semaglutide's GLP-1 side-effect profile (nausea, vomiting, diarrhea, constipation). CagriSema adds cagrilintide's amylin receptor activity, which may influence satiety signaling and gastric motility differently. The REDEFINE-1 trial reported a broadly similar tolerability profile to semaglutide monotherapy.

Why does CagriSema cause more weight loss than Wegovy?

Wegovy works through GLP-1 receptor agonism alone (semaglutide 2.4 mg). CagriSema adds cagrilintide — a long-acting amylin analogue — which activates a separate satiety and glycemic-control pathway via amylin receptors in the brainstem. This complementary dual mechanism appears to produce additional weight reduction beyond what GLP-1 agonism alone achieves.

References

  1. 1.Garvey WT, Blüher M, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity (REDEFINE 1) N Engl J Med. 2025;393(7):635-647. 2025. PMID: 40544433.
  2. 2.Yamauchi T, Becker NP, Hagemann CA, et al. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity Lancet Diabetes Endocrinol. 2026;14(6):450-462. 2026. PMID: 42009015.
  3. 3.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) N Engl J Med. 2021;384(11):989-1002. 2021. PMID: 33567185.
  4. 4.Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes (SELECT) N Engl J Med. 2023;389(24):2221-2232. 2023. PMID: 37952131.
  5. 5.Verma S, Böttcher M, Brown P, et al. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1 Hypertension. 2026. 2026. PMID: 41328546.

Related comparisons

See the full drug-vs-drug verdict index or provider rankings.